Cellid, Co., Ltd. (KOSDAQ:299660)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,610.00
-125.00 (-3.35%)
Mar 28, 2025, 3:30 PM KST
-2.92%
Market Cap 76.18B
Revenue (ttm) 4.17B
Net Income (ttm) -12.26B
Shares Out 21.10M
EPS (ttm) -743.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 123,185
Average Volume 325,309
Open 3,795.00
Previous Close 3,735.00
Day's Range 3,590.00 - 3,800.00
52-Week Range 1,733.00 - 17,310.00
Beta 1.36
RSI 35.37
Earnings Date n/a

About Cellid,

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2006
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 299660
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.